Presolicitation
Notice of Intent - Nucleic acid–based reagents for in vivo transient protein expression
NIH-26-006363-IntentNotice
Office of the Assistant Secretary for Administration (Asa), Program Support Center Acq MGMT SVC. In-Vitro Diagnostic Substance Manufacturing.
Response deadline
February 14, 2026 at 1:00 PM EST
Closed 260 days ago. Posted January 30, 2026, first published January 30, 2026. Scheduled to archive March 1, 2026.
Get the next one like this from Office of the Assistant Secretary for Administration (Asa) by email, the day it is posted.Find my opportunities
This one closed in 2026
13 like it are open now in in-vitro diagnostic substance manufacturing
- NOI - DNA Sequencing of Bone Marrow Failure Syndro
National Institutes of Health, National Institutes of Health Olao
Combined synopsis and solicitationNAICS 325413Anywhere in the US75N98027Q00027Closes tomorrowNov 2 - HEMOCHRON SIGNATURE ELITE REAGENTS AND SUPPLIES
Department of Veterans Affairs, 262-Network Contract Office 22
Sources soughtNAICS 325413Anywhere in the US36C26227Q0046Closes tomorrowNov 2 - DRESSING, DRAWTEX 4IN X 4IN (VA-27-00014447)
Department of Veterans Affairs, National Cmop Office
Sources soughtNAICS 325413Anywhere in the US36C77027Q0015Closes in 2 daysNov 3
Description
As published on SAM.gov.
This notice is not a request for competitivequotations or capability statements. The intent of this notice is for informational purposes only.
Please do not call or submit questions/inquiries via email, concerning this presolicitation notice update.
------------------------------------------------------------------------------------------------------------------------
The intent is to award a contract on a solesource basis instead of competititon for Nucleic acid–based reagents for in vivo transient protein expression forthe National Cancer Institute and Center for Cancer Research.
The supplies required are nucleic acid-based reagents.
The proposed work focuses on the use of nucleic acid-based reagents to investigate preventive strategies against viral infection of HIV/Simian Immunodeficiency virus (SIV) and HTLV in preclinical models. The proposed studies will utilize nucleic-acid based reagents that express viral antigens as a preventive treatment to be tested in appropriate models.
Nucleic acid-based reagents have been used in prior preclinical studies, conducted by the AMRVS, as preventive countermeasures against viral infections, demonstrating the ability to induce protective immune responses in relevant experimental models. Previous work has shown that such reagents can be designed to express viral antigens that are safe and confer protection against the target pathogen. Collectively, these findings support further preclinical studies as preventive strategies. The requested reagents will provide broader activity against related viral subtypes and other cancer-inducing viruses. It is important to use the same supplier for these reagents in order to ensure consistency with materials used in previous preclinical studies. These reagents can vary in formulation, synthesis methods and purity, and such differences may introduce variability that complicates interpretation of experimental results. Using reagents from the same suppliers enables direct comparison with previously generated data, support reproducibility and ensure continuity in experimental design and data analysis.
Publications
Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.
January 30, 2026
Presolicitation
Due February 14, 2026 at 1:00 PM EST. SAM.gov, notice 16f0d3a0ac4244809319904e2656f3c7
2 revisions on SAM
- January 30, 2026: publish, presolicitation
- January 30, 2026: publish, presolicitation
January 30, 2026
Presolicitation
Due February 14, 2026 at 1:00 PM EST. SAM.gov, notice e3675be32c5f47f3801816ac68017a33
2 revisions on SAM
- January 30, 2026: publish, presolicitation
- January 30, 2026: publish, presolicitation
Points of contact
- Ivan Mora-Juarezivan.mora-juarez@hhs.gov3014430055